AMANDA HALL: Open Payments
NPI 1124699178 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$470 in 27 payments from 11 companies in 2025. Trend: 2023 $622 · 2024 $370 · 2025 $470
Food & beverage: $470
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $162 |
| GENZYME CORPORATION | 2 | $50 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 5 | $41 |
| Janssen Biotech, Inc. | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $32 |
| Ardelyx, Inc. | 2 | $32 |
| Lilly USA, LLC | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: LINZESS, CREON, DUPIXENT, IQIRVO, VOQUEZNA, TREMFYA, XIFAXAN, IBSRELA.
Industry payments across NE — which companies pay providers there.
